ICE-PCS 6-Month Mortality Risk Calculator

Clinical calculation support · Verify results before clinical use

Six-month mortality assessment

Enter the patient's clinical characteristics to calculate the published simplified score.

Prognostic score

Host factors

Select the category used in the original score.

IE characteristics

Healthcare-associated infective endocarditis.

Select the microbiological category.

Complications and treatment

Model variable only; not a recommendation to operate.

About the ICE-PCS model

The ICE-PCS model was developed to estimate six-month mortality in infective endocarditis. The simplified score combines host factors, IE characteristics, complications, and surgical treatment during the index hospitalization.

Published score weights

VariableWeight
Constant4
Age ≤45 / 46–60 / 61–70 / >70 years0 / 2 / 3 / 4
History of dialysis+3
Nosocomial IE+2
Prosthetic IE+1
Symptoms >1 month before admission−1
S. aureus / viridans group streptococci+1 / −2
Aortic / mitral vegetation+1 each
NYHA class III or IV heart failure+3
Stroke+2
Paravalvular complication+2
Persistent bacteremia+2
Surgical treatment during index hospitalization−2

The publication reports the score-to-mortality relationship as 2.416 × score + 0.109 × score² − 4.849 (percentage estimate).

Reference

Park LP, Chu VH, Peterson G, et al.; International Collaboration on Endocarditis Investigators.Validated Risk Score for Predicting 6-Month Mortality in Infective Endocarditis. J Am Heart Assoc. 2016;5(4):e003016. DOI: 10.1161/JAHA.115.003016. PMID: 27091179.

Published model performance

Harrell's C statistic was 0.715 in the ICE-PCS derivation cohort and 0.682 in the ICE-PLUS validation cohort. Performance may differ in other populations.

Clinical disclaimer: For clinician education and decision support only; do not use as the sole basis for treatment decisions. Surgery is an observational prognostic variable in this model and must not be interpreted as proof of causal benefit or as a recommendation to operate. Confirm applicability to the local population before clinical use.